

#### **NEWS RELEASE**

# CHAMPIGNON ANNOUNCES FILING OF BUSINESS ACQUISITION REPORTS AND APPOINTMENT OF DIRECTOR

**VANCOUVER, British Columbia, July 24, 2020** – Champignon Brands Inc. ("**Champignon**" or the "**Company**") (**CSE: SHRM**) (**FWB: 496**) (**OTCQB: SHRMF**) is pleased to announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Copies of the reports are available for review under the Company's profile on SEDAR (www.sedar.com).

The filings are part of Champignon's commitment to work with the British Columbia Securities Commission to complete its previously announced disclosure review in a timely fashion. The review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020, and includes a review of the disclosure surrounding recent acquisitions completed by the Company.

Champignon also announces it has appointed Dr. Roger McIntyre, Champignon CEO, to its Board of Directors. Dr. McIntyre's appointment will replace Pat McCutcheon's position as a director of the Company. Mr. McCutcheon will remain with the Company in an advisory capacity, which will permit him increased mobility to assist the Company with ongoing and planned capital markets initiatives.

### ON BEHALF OF THE BOARD OF DIRECTORS

Dr. Roger McIntyre Chief Executive Officer

E: <u>info@champignonbrands.com</u>

#### FOR INVESTOR INQUIRIES:

Champignon Brands | Storyboard Communications Investor Relations, Toronto, Canada Investor Line: +1 (833) 375-9995 x611

E: <a href="mailto:champignonbrands@storyboardcommunications.com">champignonbrands@storyboardcommunications.com</a>

# FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:

Remy Scalabrini Maricom Inc.

E: <u>rs@maricom.ca</u> T: +1 (888) 585-MARI The CSE and its Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

## Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements we make regarding the speed and effectiveness of our treatments are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company's limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company's industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws; failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; and failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.